Results 161 to 170 of about 2,105 (188)
Matrix Metalloproteinase Inhibitor, Marimastat, Decreases Peritoneal Spread of Gastric Carcinoma in Nude Mice [PDF]
Japanese Journal of Cancer Research, 2002 Marimastat, a matrix metalloproteinese inhibitor, was examined for the ability to prevent peritoneal dissemination of a human gastric cancer xenograft, TMK–1. Even with novel approaches such as molecular targeting of cancer chemotherapy, peritoneal dissemination of gastric cancer has little sensitivity to anticancer drugs, and it is impossible to ...
Yasunori Okada
exaly +3 more sources
Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen [PDF]
British Journal of Cancer, 1999 Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological response was made by measurement of carcinoembryonic antigen (CEA) levels.
H Bleiberg, M Seymour, J L Mansi
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Trends in Biotechnology, 2001
Marimastat, the matrix-metalloproteinase inhibitor developed by British Biotech (Oxford, UK), produces survival rates comparable to chemotherapy in patients suffering from non-metastatic pancreatic cancer (Journal of Clinical Oncology, 1 August). When trialled against the chemotherapeutic agent gemcitabine, one-year survival rates for patients taking ...
openaire +1 more source
Marimastat, the matrix-metalloproteinase inhibitor developed by British Biotech (Oxford, UK), produces survival rates comparable to chemotherapy in patients suffering from non-metastatic pancreatic cancer (Journal of Clinical Oncology, 1 August). When trialled against the chemotherapeutic agent gemcitabine, one-year survival rates for patients taking ...
openaire +1 more source
ChemInform Abstract: Five‐Component Synthesis of Marimastat Analogues.
ChemInform, 1999AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
S. PATEL +4 more
openaire +1 more source
Batimastat and Marimastat in Cancer
1999Batimastat® and Marimastat® are broad-spectrum matrix metalloproteinase inhibitors (MMPI) with potent activity against most of the major matrix metalloproteinases (MMPs). Batimastat is the prototype MMPI, and is highly active against interstitial collagenase (MMP-1) (IC50 = 3 nM), stomelysin-1 (MMP-3) (IC50 = 20 nM), gelatinase-A (MMP-2) (IC50 = 4 nM),
openaire +1 more source
Ras-transfection up-regulated HaCaT cell migration: Inhibition by Marimastat
Clinical & Experimental Metastasis, 1999Cell migration is an essential process in physiological and pathological conditions such as wound healing and tumor invasion. This phenomenon involves cell adhesion on the extracellular matrix mediated by integrins, and cell detachment promoted in part by metalloproteinases (MMPs). In the present study, the migration of two HaCaT-ras clones (metastatic
S, Charvat +4 more
openaire +2 more sources
An improved synthesis of the broad spectrum matrix metalloprotease inhibitor marimastat
Tetrahedron Letters, 2000Abstract A considerably shortened synthesis of the broad spectrum matrix metalloproteinase (MMP) inhibitor marimastat has been achieved by a direct hydroxylamino ring opening of a key acetonide intermediate.
Richard J Davenport, Robert J Watson
exaly +2 more sources
Arthritis & Rheumatism, 2003
AbstractObjectiveTo characterize the clinical and histopathologic changes in a rat model of broad‐spectrum matrix metalloproteinase (MMP)–induced musculoskeletal syndrome (MSS), and to facilitate research into the causes and treatments of MSS in humans.MethodsMale Lewis rats weighing 150–180 gm were administered 10–30 mg of the broad‐spectrum MMP ...
Richard, Renkiewicz +8 more
openaire +2 more sources
AbstractObjectiveTo characterize the clinical and histopathologic changes in a rat model of broad‐spectrum matrix metalloproteinase (MMP)–induced musculoskeletal syndrome (MSS), and to facilitate research into the causes and treatments of MSS in humans.MethodsMale Lewis rats weighing 150–180 gm were administered 10–30 mg of the broad‐spectrum MMP ...
Richard, Renkiewicz +8 more
openaire +2 more sources
Effect of marimastat on serum tumour markers in patients with colorectal cancer.
International journal of surgical investigation, 2003Matrix metalloproteinases (MMPs) are a family of enzymes that break down extra cellular matrix proteins during tissue formation. Tumours have been shown to over-express certain matrix metalloproteinases relative to normal tissue. Matrix metalloproteinases are associated with the disruption of tissue architecture in the growth of tumours and they are ...
H, North, J, King, D L, Morris
openaire +1 more source
Tumour marker levels during marimastat therapy
The Lancet, 1996A Millar, P Brown, A Cornish, M Baillet
openaire +2 more sources